Drug intelligence / Profile preview

BMS-986458 (Bristol Myers Squibb)

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

BMS-986458 is an investigational small molecule dual inhibitor of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGLL). Developed by Bristol Myers Squibb, it is designed to increase the levels of endogenous cannabinoids, such as anandamide and 2-arachidonoylglycerol, by inhibiting the enzymes responsible for their degradation. This elevation of endocannabinoids is hypothesized to provide therapeutic benefits by modulating neurotransmission and reducing neuroinflammation. The drug is currently being evaluated in Phase 2 clinical trials for the treatment of agitation associated with Alzheimer's disease and spasticity in patients with multiple sclerosis.

Other names: FAAH/MGLL inhibitorFAAH/MAGL inhibitorfatty acid amide hydrolase/monoacylglycerol lipase dual inhibitor

Targets

BCL6 (B cell lymphoma 6 protein)CRBN (Cereblon)

Beyond the preview

Go deeper on BMS-986458 (Bristol Myers Squibb).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-986458 (Bristol Myers Squibb).

Explore the full profile